Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2015-11-09Clinical Trial Update: Can Genetics Predict Treatment Response to a Computerized Self-help Program for Depression? [NA]
This completed clinical trial examines whether genetic factors can predict treatment response to a computerized self-help program in individ…
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder [Phase 2]
A Phase 2 study evaluating the safety and tolerability of OPC-34712 as adjunctive therapy for adults with Major Depressive Disorder has comp…
-
CLINICAL_TRIALS trial_result · 2015-11-03Clinical Trial Update: Creating African-American Wellness Through Exercise [NA]
A clinical trial titled 'Creating African-American Wellness Through Exercise' sponsored by Oregon Health and Science University focusing on …
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder [Phase 2]
Phase 2 study evaluating OPC-34712 as adjunctive therapy for adults with major depressive disorder; trial completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2015-10-29Clinical Trial Update: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants [Phase 1]
Phase 1 pharmacokinetics study of five antipsychotic medications in psychiatric participants has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-10-28FDA Approved: ESCITALOPRAM — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
The FDA approved Jubilant Cadista's supplemental application for escitalopram oxalate, a generic version of escitalopram.
-
FDA approval · 2015-10-28FDA Approved: DULOXETINE — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' original ANDA for duloxetine, allowing a generic version to be marketed. The approval covers duloxetin…
-
FDA approval · 2015-10-23FDA Approved: ESCITALOPRAM ORAL SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for escitalopram oral solution from Chartwell RX, LLC, enabling a generic oral formulation. This app…
-
CLINICAL_TRIALS research · 2015-10-23Clinical Trial Update: Working Memory Training in Adults With Substance Abuse and Executive Function Deficits. [Phase 2]
A Phase 2 clinical trial update on working memory training for adults with substance use disorder and related cognitive and mood comorbiditi…
-
CLINICAL_TRIALS research · 2015-10-22Clinical Trial Update: Supportive Expressive Therapy for Depressed and Anxious Adolescents [NA]
A completed clinical trial on supportive expressive therapy for depressed and anxious adolescents, sponsored by the Centre for Addiction and…
-
CLINICAL_TRIALS trial_result · 2015-10-21Clinical Trial Update: Depression and Congestive Heart Failure in Outpatients. [NA]
This clinical trial update reports that a study on depression and congestive heart failure in outpatients has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2015-10-21Clinical Trial Update: Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 [Phase 1]
Phase 1 multiple ascending dose study in healthy subjects evaluated the safety, tolerability, and pharmacokinetics of LY03005. The trial has…
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
A clinical trial registry study of patients treated with atypical antipsychotics has completed enrollment and is reporting on outcomes acros…
-
FDA label_change · 2015-10-19FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Escitalopram Oxalate by Exelan Pharmaceuticals, indicating a change to the drug's labeling under…
-
FDA approval · 2015-10-16FDA Approved: EMSAM — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for EMSAM (selegiline transdermal patch) from Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2015-10-14Clinical Trial Update: Major Depressive Disorder With Mixed Features - Extension [Phase 3]
Extension of a Phase 3 trial in major depressive disorder with mixed features; results were posted in 2015.
-
CLINICAL_TRIALS withdrawal · 2015-10-14Clinical Trial Update: Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder [NA]
A clinical trial evaluating an electronic cognitive behavioral therapy application for treating Major Depressive Disorder has been withdrawn…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression [Phase 2]
This Phase 2 trial evaluated the efficacy and safety of fixed doses of BMS 820836 in patients with treatment-resistant major depression. The…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression [Phase 2]
A Phase 2 trial evaluating the efficacy and safety of flexibly dosed BMS-820836 in patients with treatment-resistant major depressive disord…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Cognitive and Drug Therapy for Drug-Resistant Depression [NA]
A completed clinical trial evaluating cognitive and pharmacologic therapies for treatment-resistant depression.
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression [Phase 2]
Phase 2 long-term safety and tolerability study of BMS-820836 in treatment-resistant major depression was terminated; the update provides sa…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose [Phase 3]
A Phase 3 trial evaluating a flexible-dose regimen for Major Depressive Disorder with mixed features has completed and results were posted i…
-
CLINICAL_TRIALS research · 2015-10-09Clinical Trial Update: Comparison of Positive Psychotherapy and Cognitive-Behavioral Psychotherapy for Depression [NA]
Clinical trial update comparing Positive Psychotherapy with Cognitive-Behavioral Therapy for depression; no results or current status detail…
-
CLINICAL_TRIALS trial_result · 2015-10-08Clinical Trial Update: Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy [Phase 3]
Phase 3 trial results for brexpiprazole as adjunctive therapy in adults with major depressive disorder with inadequate response to prior adj…
-
CLINICAL_TRIALS research · 2015-10-07Clinical Trial Update: Complex Dynamic Systems in Mood Disorders
An update on a completed clinical trial at Massachusetts General Hospital exploring complex dynamic systems in mood disorders. The condition…